Posters Thursday Morning (group I)
1. Isabel Gonzalez-Alvarez Pharmacokinetics and bioavailability of new ciprofloxacin derivative (CNV 97101) in rat: repercussion of precipitation in stomach.
2. Déborah Hirt Age-related effects on nelfinavir - M8 pharmacokinetics - A population study in 182 children
3. Xavière Panhard High Inter-Patient Variability of Pharmacokinetics of Lamivudine (LMV), Stavudine (STV) and Zidovudine (ZDV) in HIV-Infected Patients treated with HAART (Cophar 1 – ANRS 102 Study).
4. Maria Rosario Model-based drug development of a new anti-HIV drug
5. María José García Sánchez Vancomycin population pharmacokinetic analysis in patients with hematological malignancies
6. Vincent Jullien Population pharmacokinetics of tenofovir in HIV-infected patients taking highly active antiretroviral therapy.
7. José Moltó Population pharmacokinetics of lopinavir in HIV-infected adults receiving lopinavir/ritonavir
8. Christine Staatz Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery
9. Stephanie Chantel Pharmacokinetics modelling and anti-Xa level simulation of enoxaparin used for venous thromboembolism prophylaxis after orthopaedic surgery
10. Stephanie Chantel Population pharmacokinetics of enoxaparin used for thromboembolism prophylaxis after total hip replacement
11. Bruce Green Use of an indirect effect model to describe the mobilization of progenitor cells induced by AMD3100
12. Anna-Karin Hamberg Pharmacokinetic/Pharmacodynamic Modelling of the Anticoagulant Activity of Warfarin
13. Karl-Heinz Liesenfeld PK/PD-Modeling (PK/PD) and Clinical Trial Simulation (CTS) of Early Clinical Data of a New Oral Direct Thrombin Inhibitor (Dabigatran Etexilate)
14. Juan Jose Perez Ruixo Population Pharmacokinetics of rHuEpo in Healthy volunteers.
15. Ekaterina Gibiansky Population PK/PD model of GPI 15715 and GPI-derived propofol in sedation and comparison of PK/PD models for ordered categorical observations
16. Berangere Gruwez A mathematical model for paroxetine antidepressant effect time course and its interaction with pindolol
17. Thorsten Lehr A new CNS active drug and its metabolite: a population pharmacokinetic analysis
18. Lia Liefaard Population Pharmacokinetic/Pharmacodynamic Analysis of Different Subunit Selective GABAergic Ligands in an Animal Model of Epilepsy
19. Gianluca Nucci Population pharmacokinetics of paroxetine in the pediatric population
20. Etienne Pigeolet Retrospective Population Pharmacokinetic Analysis of Levetiracetam in Westerner and Japanese Adults
21. Olivier Petricoul Understanding the variability in clinical response to rufinamide, a new antiepileptic drug: a pooled PKPD analysis
22. Nuria Rivas Population pharmacokinetics of lamotrigine in epileptic patients with data proceeding of therapeutic drug monitoring
23. Gijs Santen Modelling of the Hamilton Depression Rating Scale in Unipolar Depression Trials
24. Brunhild Schiltmeyer Population pharmacokinetics of the new antiepileptic drug lacosamide in healthy subjects with different age and gender
25. Armel Stockis Dose-response analysis of levetiracetam add-on treatment in patients with partial epilepsy
26. Ashley Strougo PK and PK/PD Modelling of CNS Effects and Heart Rate After THC Administration in Humans
27. An Vermeulen Population PK/PD modeling of supine heart rate after oral administration of a new candidate antipsychotic drug
28. Jeffrey Wald Model Based Insights to Lamotrigine for Pain Associated with Diabetic Peripheral Neuropathy
Posters Thursday Afternoon (group II)
30. Vincent Duval Ivabradine and S18982 activities on heart rate: a population PK/PD analysis
31. Christine Falcoz Strategies to Improve Model-based Decision-making During Clinical Development
32. Gabriele Fliss Development and evaluation of a population pharmacokinetic model for cilobradine, an If channel blocker
33. Annabelle Lemenuel-Diot Use of Time-to-event analysis to qualify activity of Ivabradine durign exercise tolerance tests
34. Mathilde Marchand The effect of rufinamide concentration on the QT interval in healthy subjects treated during 18 days with multiple ascending doses: a population PKPD analysis.
35. Takahiko Tanigawa A population PK model for nifedipine coat-core tablet
36. Démiana William Faltaos Use of an indirect effect model to describe the LDL Cholesterol lowering process by statins
37. Josep Maria Cendrós Population pharmacodynamic modelling of lanreotide (Lan) autogel (ATG) in patients with acromegaly
38. Mats Karlsson Pharmacokinetic and pharmacodynamic modelling of the dual PPAR α/γ agonist tesaglitazar in patients with manifestations of insulin resistance
39. Mats Karlsson A pooled population pharmacokinetic analysis of tesaglitazar in patients with type 2 diabetes or with manifestations of insulin resistance
40. Teun Post Treatment Efficacy of Combination-Therapy based on a Mechanistic Characterisation of Disease Processes in Type 2 Diabetes Mellitus over a two-year period
41. Hanna Silber A physiology based model for the glucose-insulin regulation in healthy volunteers and diabetic patients following intravenous glucose provocations.
42. Maria Garrido Pharmacokinetics and Pharmacodynamics of Rocuronium bromide in patients undergoing brain surgery: Influence of chronic Phenytoin therapy
43. Thorsten Lehr Evaluation of an enterohepatic circulation model: predicting the influence of cholestyramine on the pharmacokinetics of meloxicam
44. Micha Levi Population Pharmacokinetics of Rituximab in RA (Rheumatoid Arthritis) Patients: Combining two phase II studies
45. Christiane Tillmann Meloxicam for juvenile rheumatoid arthritis patients: Is dosing on a mg/kg body weight basis justified?
46. Lorea Bueno Mechanistic PK/PD modelling for signal transduction modulators. Application to TGF-beta RI antagonists.
47. Helena Colom Population pharmacokinetics of high-dose methotrexate in osteosarcoma pediatric patients.
48. Anja Henningsson Population Pharmacokinetic Model for Cremophor EL
49. Markus Joerger Determinants of the pharmacokinetics of methotrexate and its metabolite 7-hydroxy-methotrexate following high-dose infusional methotrexate
50. Angelica Quartino Population Based Pharmacodynamics for In Vitro Drug Sensitivity Assays: Prediction of Model Based Parameters of Drug Activity and Relationship to Clinical Outcome
51. Diane Testart PK-PD model compared with K-PD model to predict haematotoxicity induced by anticancer drugs.
52. Laura Zufía Pharmacokinetics of paclitaxel in liver transplantation cancer patients
53. Laura Zufía Tegafur and 5-Fluorouracil pelvic tissues concentrations in rectal cancer patients treated with preoperative chemoradiation. The processed sample stability investigation and their impact in the reability of data
54. René Bruno Modelling and Simulation of the Telephone Sexual Activity Daily Diary (TSADD) Data of patients with female sexual arousal disorder (FSAD) treated with sildenafil (Viagra).
55. Xuejun Chen Modeling of circadian effect on lung function in patients with chronic obstructive pulmonary disease
56. John Lukas Pharmacokinetics-guided targeting of mycophenolate mofetil (MMF) in combination renal transplantation treatment confirms the need for dose reduction
Posters Friday Morning (group III)
57. Marylore Chenel Optimal blood sampling time windows for parameter estimation using a population approach: design of a Phase II clinical trial
58. Doaa Elsherbiny Population pharmacokinetics of S-mephenytoin and its metabolites S-nirvanol and S-4-hydroxymephenytoin in CYP2C19 poor, intermediate and extensive metabolizers.
59. Ivelina Gueorguieva Population Optimal Design for Multivariate Response Pharmacokinetic Models
60. Andrew Hooker Simultaneous population D-optimal designs for contrast enhanced MRI measurements of atherosclerotic plaque neovasculature.
61. Patrick Johnson Optimising PK sampling under the constraint imposed in later phase clinical trials
62. Kristin Karlsson Randomized exposure-controlled trials; impact of randomization and analysis strategies – from a toxicity perspective
63. Sylvie Retout Relevance of the use of population design evaluation and optimisation methods in the context of drug development projects in Roche
64. Sylvie Retout Designs in nonlinear mixed effects models: application to HIV viral load decrease with evaluation, optimization and determination of the power of the test of a treatment effect
65. Larisa Reyderman Designing Sparse-Sampling Schemes for Population PK Study of a Highly Variable Drug.
66. Oleg Volkov Patients’ Non-compliance with Drug Administration Times and Optimal Population Design in Pharmacokinetics
67. Liping Zhang Analyzing Multi-response Data Using Forcing Functions: illustrated in pharmacokinetic physiological flow modeling
Methodology: General (I)
68. Kristin Carlsson Bioavailability of gabapentin assessed by cumulative urine sampling compared with a model for the saturated absorption of gabapentin.
69. Anne Chain Separating Signal from Noise: PK/PD modelling of QT-interval prolongation
70. S. Y. Amy Cheung Structural identifiability analysis of some semi-physiologically based and whole body physiologically based (WBPBPK) pharmacokinetic models.
71. Shafi Chowdhury Producing NONMEM dataset using a standard SAS® program
72. Emmanuelle Comets Building a pharmacogenetic model to describe the pharmacokinetics of digoxin
73. Valerie Cosson Modelling placebo response in depression using a mechanistic longitudinal model approach
74. Aris Dokoumetzidis Propagation of population PK and PD information using a Bayesian approach: dealing with non-exchangeability
75. Stephen Duffull A Semi-Mechanistic Model For Quantification Of Lean Body Weight
76. Jan Freijer Robust fitting of pharmacokinetic models to Phase II/III clinical trial data
77. Massimiliano Germani Implementation of variability in a physiologically-based pharmacokinetic approach for simulating the first-in-animal study
78. Leonid Gibiansky NMQual: A Tool to Automate Installation and Facilitate Qualification of NONMEM
79. Nick Holford Topical Corticosteroid Bioequivalence – An Evaluation of the FDA Guidance
80. Nick Holford Simultaneous modelling of disease progression and time to event with NONMEM – likelihood ratio test criteria for random and informative dropout models and an evaluation of two methods affecting the quality of parameter estimates
81. Iñaki Trocóniz A New Model to Describe the Bradycardic Effects of If channel blockers in Healthy Volunteers
Posters Friday Afternoon (group IV)
Methodology: General (II)
82. Hannah Jones Prediction of drug-drug interactions and their associated variability in human populations: Application to erlotinib and its coadministration with ketoconazole and rifampicin
83. Thomas Kerbusch The Efficiency of Mixed Effect Modelling to Detect Metabolism-Based Drug-Drug Interactions (mDDI)
84. Andreas Krause Modeling Discontinuation of Treatment in Non-Ignorable Situations
85. Marc Lavielle Estimation of population pharmacokinetic parameters of saquinavir in HIV patients and covariate analysis with MONOLIX
86. Thorsten Lehr Assessment of the potency of a metabolite relative to the parent compound using a population PK/PD model for the inhibition of a neurotransmitter re-uptake transporter in mice
87. Raymond Miller Exposure-Response Analysis Using Time to Event Data: An Example Using Sleep Onset.
88. Elisabet Nielsen A Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model for Antibiotics
89. Vladimir Piotrovsky Indirect-response model for the analysis of concentration-effect relationships in clinical trials where response variables are scores
90. Jakob Ribbing The Lasso - A Novel Method for Predictive-Covariate Modelling of Population Pharmacokinetics/Pharmacodynamics
91. Adeline Samson Generalisation of the SAEM algorithm to nonlinear mixed effects model defined by differential equations : application to HIV viral dynamic models
92. Walter Schmitt Prediction of Clearance in Children Using a Combined Physiology-based and Enzyme Ontogeny Approach
93. Walter Schmitt Predicting pharmacokinetics in children using PK-Sim®
94. Monica Simeoni Counting events: population approaches using NONMEM
95. Nicolas Simon Cluster analysis : an alternative method for covariate selection in population pharmacokinetics modeling
96. Stacey Tannenbaum A Novel Method for Simulation of Correlated Continuous and Categorical Variables Using A Single Multivariate Distribution
97. Eric Tousset Non-Adherence to Prescribed Therapy is a Major Obstacle for Population PK/PD Studies
98. Tamara van Steeg The influence of an increase in plasma protein binding on the pharmacokinetics and pharmacodynamics of S(-)-Propranolol
99. Justin Wilkins Predicting recovery progression in acute stroke using the Barthel Index
100. Miren Zamacona Modelling time varying kinetics using time dependent feedback control on clearance
101. Stefano Zamuner Use population approach to characterize PK time-course with erratic absorption
102. Per-Henrik Zingmark Modelling a spontaneously reported side-effect by use of a Markov mixed-effects model
103. Klaas Zuideveld Agonist-antagonist interaction models with slope factor: implications of an alternative derivation
Methodology: Model evaluation
104. Karl Brendel Metrics based on objective function for external validation of a population pharmacokinetic model
105. Nick Holford The Visual Predictive Check – Superiority to Standard Diagnostic (Rorschach) Plots